JAK2 and non-small cell lung carcinoma: JAK2 inhibition abrogates proliferation in NSCLC cell lines, including those that are TKI‐resistant 55, and several reports showed that inhibition of STAT3 and STAT5 suppresses the growth of cancer cells and enhances the sensitivity to anticancer drugs in multiple types of cancers 30, 56, 57, 58.